Microglia play protective role in response to retinal detachment, shows study

NewsGuard 100/100 Score

A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the brain and retina, play a protective role in response to retinal detachment. Retinal detachment and subsequent degeneration of the retina can lead to progressive visual decline due to photoreceptor cell death, the major light-sensing cell in the eye. In a report published online today in the journal Proceedings of the National Academy of Sciences (PNAS), the researchers describe, for the first time, the beneficial role of microglial cells in the eye after retinal detachment -; migrating to the site of injury to protect photoreceptors and to regulate local inflammation.

"Our results provide clear evidence that microglia protect photoreceptors from cell death in acute retinal detachment," said senior author Kip Connor, Ph.D., vision researcher at Mass. Eye and Ear and Assistant Professor of Ophthalmology at Harvard Medical School. "We found that microglial cells rapidly migrate into the injured retina, where they formed close connections with infiltrating immune cells and removed injured photoreceptors. These findings provide the first insight into how microglia respond and function during retinal detachment."

Affecting about 200,000 Americans per year, retinal detachments are considered sight-threatening medical emergencies. When the retina detaches from its normal position, it separates the blood vessels that supply oxygen to the eye, and photoreceptors -; the major light-sensing cells of the retina -; begin to die away. Retinal detachments can occur spontaneously, as a result of blunt trauma or as a side effect of a variety of eye diseases, including diabetic retinopathy, ocular tumors, and age-related macular degeneration.

The current standard of care for retinal detachment is surgical reattachment, with patients in the United States and Europe typically treated within one week. Today's surgical techniques are highly effective in physically reattaching the retina, and – if surgery is timely – surgical outcomes are generally positive. However, in some cases, patients experience permanent vision loss accompanied by changes in color vision.

Researchers around the world -; across all fields of medicine -; have recently begun to shed light on the function of microglial cells in various conditions. In Alzheimer's, Parkinson's and other neurodegenerative diseases of the brain, they are thought to be harmful.

In the ophthalmology setting, microglial cells have been known to be activated in retinal detachment; however, it was previously unknown if these cells were harmful or protective against photoreceptor cell death.

In the PNAS report, the researchers describe morphological changes in microglia in response to retinal detachment in a preclinical model. In response to retinal detachment, microglia rapidly responded in a uniform migrating pattern, toward the affected area. When the researchers depleted microglia in the model, they saw more of the photoreceptor cells die away.

The authors on the PNAS report are hopeful that these findings suggest a new therapeutic avenue for preserving photoreceptors after retinal detachment.

"Clinically, in the context of retinal detachment, we think promoting these cells would be of significant therapeutic benefit -; perhaps early on, when they can keep inflammation in check," said Yoko Okuniki, M.D., Ph.D., a postdoctoral fellow at Mass. Eye and Ear and the study's lead author. "This could prevent the initial photoreceptor cell loss, preserving vision longer after retinal detachment and providing an extended therapeutic window for surgery."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Google Gemini and Bard pass the ophthalmology board examination